A Phase 3 interventional study of Apalutamide and Placebo in Prostatic Neoplasms, sponsored by Aragon Pharmaceuticals, Inc.. Active, not recruiting at 379 sites in 25 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Aragon Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.
Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 4th largest by enrollment, is one of 3 that started in 2013, is one of 16 in phase 3, reaches primary completion later than 1 of the 35 other live ones, and was the 4th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
Marco Oderda · Sites in Italy
Ages 18–80 · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+ · Men only
Cambridge University Hospitals NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Men only
By country, each count listing its studies:
apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 39 · Phase 3 16 · Phase 4 2
First in 2010; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,207 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 81 across the 70 interventional studies. Of the 29 that completed or were terminated, 16 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 70 have an industry lead sponsor. The 10 most frequent:
This study is registered under Aragon Pharmaceuticals, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Aragon Pharmaceuticals, Inc. is the lead sponsor of 16 studies on the registry; none are open to participants now.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 4th largest by enrollment of the 68 interventional ones that give a count, is one of 8 that started in 2013, is one of 15 in phase 3, reaches primary completion later than 1 of the 22 other live ones, and was the 37th registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
9 of the studies testing apalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
| NCT06274047Phase 3M.D. Anderson Cancer CenterPROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. | 2027-06-30 |
| NCT06067269Jonsson Comprehensive Cancer CenterHormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial | 2026-12-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 70 studies testing apalutamide in Prostatic Neoplasms, from their registry updates:
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.
This Phase 3 clinical trial is an essential step in the evaluation of an investigational medication to see if it may be useful in treating prostate cancer. The purpose of the SPARTAN study is to compare the safety and effectiveness of the investigational medication to placebo in delaying prostate cancer from spreading to other parts of the body. A placebo is a pill that looks like the investigational medication but does not contain any active medication, a dummy pill.
Phase 3 studies are performed after preliminary evidence suggesting effectiveness of the drug has been obtained in previous Phase 2 studies. These studies are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug.
Study participants will take the oral investigational medication daily. One cycle of study treatment lasts 4 weeks or 28 days. The number of cycles will depend on how you and your cancer respond to the study medication.
In order for the researchers to evaluate and compare the study results, there are two different study groups. Study participants will be randomly (like flipping a coin) assigned to one of these groups:
The investigational medication will be given to 2 out of every 3 study participants. Neither you nor the study staff will know which group you are in. However, in case of a medical emergency, your study doctor can quickly find out which treatment group you are in.
All participants will continue to receive their current treatment along with either the investigational medication or a placebo. The selections will be random, and you may remain on investigational treatment until your disease worsens, or until significant side effects occur or you can no longer tolerate treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Apalutamide
Drug: Placebo
240 mg tablets administered by mouth on a continuous once daily dosing regimen
Matched placebo tablets administered by mouth on a continuous once daily dosing regimen
Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR)
MFS was defined as the time from randomization to the time of first evidence of BICR-confirmed bone or soft tissue distant metastasis or death due to any cause, whichever occurred first. The MFS data for participants without metastasis or death were performed for US or ex-US regulatory purposes. Radiographic scans (bone scans and computerized tomography \[CT\] or magnetic resonance imaging \[MRI\] of the chest, abdomen, and pelvis) were performed for detection of metastasis throughout the study.
Time frame: Up to approximately 43 Months
Time to Metastasis (TTM)
Time to metastasis (TTM) was defined as the time from randomization to the time of the scan that showed first evidence of BICR-confirmed radiographically detected bone or soft tissue distant metastasis. The TTM data for participants without metastasis were performed for US or ex-US regulatory purposes. Radiographic scans (bone scans and CT or MRI of the chest, abdomen, and pelvis) were performed for detection of metastasis throughout the study.
Time frame: Up to approximately 43 Months
Progression-free Survival (PFS)
PFS defined as time from randomization to first documentation of BICR-confirmed radiographic progressive disease (PD) (development of distant/local/regional metastasis)/death due to any cause whichever occurred first. PFS data for participants without loco-regional disease were performed for US/ex-US regulatory purposes. Radiographic scans (bone scans and CT/MRI of chest,abdomen,pelvis) performed for detection of metastasis throughout study. PD based on RECIST v1.1; Subjects with one measurable lesion, At least 20% increase in sum of diameters of target lesions taking as reference smallest sum on study. In addition, sum must demonstrate an absolute increase of at least 5 millimeter(mm). Also, appearance of one/more new lesions was also considered PD. Subjects with non-measurable disease as per CT/MRI scans, unequivocal progression/appearance of one or more new lesions was considered PD. For new bone lesions detected on bone scans, second imaging (CT/MRI) was required to confirm PD.
Time frame: Up to approximately 43 Months
Time to Symptomatic Progression
Time to symptomatic progression was defined as the time from randomization to documentation in the CRF of any of the following (whichever occurred earlier): a) development of a skeletal-related event (pathologic fracture, spinal cord compression, or need for surgical intervention or radiation therapy to the bone); b) pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anti-cancer therapy; or c) development of clinically significant symptoms due to loco-regional tumor progression requiring surgical intervention or radiation therapy.
Time frame: Up to approximately 43 Months
Overall Survival
Overall survival was defined as the time from randomization to the date of death due to any cause.
Time frame: Up to approximately 43 months
Time to Initiation of Cytotoxic Chemotherapy
Time to initiation of cytotoxic chemotherapy was defined as the time from randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer.
Time frame: Up to approximately 43 months
| Milestone | Placebo | Apalutamide |
|---|---|---|
| Started | 401 | 806 |
| Treated | 398 | 803 |
| Completed | 0 | 0 |
| Not completed | 401 | 806 |
| Withdrew: Death | 38 | 59 |
| Withdrew: Withdrawal by subject | 37 | 50 |
| Withdrew: Lost to follow-up | 3 | 7 |
| Withdrew: Ongoing | 316 | 687 |
| Withdrew: Other | 7 | 3 |
Time to metastasis (TTM) was defined as the time from randomization to the time of the scan that showed first evidence of BICR-confirmed radiographically detected bone or soft tissue distant metastasis. The TTM data for participants without metastasis were performed for US or ex-US regulatory purposes. Radiographic scans (bone scans and CT or MRI of the chest, abdomen, and pelvis) were performed for detection of metastasis throughout the study.
| Months | Placebo | Apalutamide |
|---|---|---|
| US Regulatory | 16.59 (14.59 to 18.46) | 40.51 (NA to NA) |
| EX-US Regulatory | 15.70 (14.55 to 18.40) | 40.51 (31.15 to 40.51) |
PFS defined as time from randomization to first documentation of BICR-confirmed radiographic progressive disease (PD) (development of distant/local/regional metastasis)/death due to any cause whichever occurred first. PFS data for participants without loco-regional disease were performed for US/ex-US regulatory purposes. Radiographic scans (bone scans and CT/MRI of chest,abdomen,pelvis) performed for detection of metastasis throughout study. PD based on RECIST v1.1; Subjects with one measurable lesion, At least 20% increase in sum of diameters of target lesions taking as reference smallest sum on study. In addition, sum must demonstrate an absolute increase of at least 5 millimeter(mm). Also, appearance of one/more new lesions was also considered PD. Subjects with non-measurable disease as per CT/MRI scans, unequivocal progression/appearance of one or more new lesions was considered PD. For new bone lesions detected on bone scans, second imaging (CT/MRI) was required to confirm PD.
| Months | Placebo | Apalutamide |
|---|---|---|
| US Regulatory | 14.72 (14.49 to 18.37) | 40.51 (NA to NA) |
| EX-US Regulatory | 14.65 (11.27 to 17.97) | 40.51 (29.40 to 40.51) |
Time to symptomatic progression was defined as the time from randomization to documentation in the CRF of any of the following (whichever occurred earlier): a) development of a skeletal-related event (pathologic fracture, spinal cord compression, or need for surgical intervention or radiation therapy to the bone); b) pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anti-cancer therapy; or c) development of clinically significant symptoms due to loco-regional tumor progression requiring surgical intervention or radiation therapy.
| Months | Placebo | Apalutamide |
|---|---|---|
| Time to Symptomatic Progression | NA (36.83 to NA) | NA (NA to NA) |
Overall survival was defined as the time from randomization to the date of death due to any cause.
| Months | Placebo | Apalutamide |
|---|---|---|
| Overall Survival | 39.03 (39.03 to NA) | NA (NA to NA) |
Time to initiation of cytotoxic chemotherapy was defined as the time from randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer.
| Months | Placebo | Apalutamide |
|---|---|---|
| Time to Initiation of Cytotoxic Chemotherapy | NA (NA to NA) | NA (NA to NA) |
MFS was defined as the time from randomization to the time of first evidence of BICR-confirmed bone or soft tissue distant metastasis or death due to any cause, whichever occurred first. The MFS data for participants without metastasis or death were performed for US or ex-US regulatory purposes. Radiographic scans (bone scans and computerized tomography \[CT\] or magnetic resonance imaging \[MRI\] of the chest, abdomen, and pelvis) were performed for detection of metastasis throughout the study.
| Months | Placebo | Apalutamide |
|---|---|---|
| US Regulatory | 16.20 (14.59 to 18.40) | 40.51 (NA to NA) |
| Ex-US Regulatory | 15.70 (14.55 to 18.40) | 40.51 (29.70 to 40.51) |
Collected over Up to approximately 43 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/398 (0.3%) | 92/398 (23.1%) | 329/398 (82.7%) |
| Apalutamide | 10/803 (1.2%) | 199/803 (24.8%) | 716/803 (89.2%) |
| Event | Placebo | Apalutamide |
|---|---|---|
| Urinary RetentionRenal and urinary disorders | 15/398 | 10/803 |
| HaematuriaRenal and urinary disorders | 8/398 | 13/803 |
| HydronephrosisRenal and urinary disorders | 8/398 | 8/803 |
| Urinary Tract InfectionInfections and infestations | 3/398 | 10/803 |
| PneumoniaInfections and infestations | 2/398 | 9/803 |
| Acute Kidney InjuryRenal and urinary disorders | 4/398 | 6/803 |
| Urinary Tract ObstructionRenal and urinary disorders | 4/398 | 2/803 |
| Atrial FibrillationCardiac disorders | 2/398 | 7/803 |
| SepsisInfections and infestations | 0/398 | 7/803 |
| Renal FailureRenal and urinary disorders | 3/398 | 3/803 |
| Event | Placebo | Apalutamide |
|---|---|---|
| FatigueGeneral disorders | 84/398 | 244/803 |
| HypertensionVascular disorders | 77/398 | 198/803 |
| DiarrhoeaGastrointestinal disorders | 60/398 | 159/803 |
| NauseaGastrointestinal disorders | 63/398 | 145/803 |
| Weight DecreasedInvestigations | 25/398 | 128/803 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 30/398 | 128/803 |
| FallInjury, poisoning and procedural complications | 35/398 | 121/803 |
| Back PainMusculoskeletal and connective tissue disorders | 59/398 | 100/803 |
| Hot FlushVascular disorders | 34/398 | 113/803 |
| ConstipationGastrointestinal disorders | 52/398 | 87/803 |
| Age, Continuous(years) | Placebo | Apalutamide | Total |
|---|---|---|---|
| Mean | 74.1 ± 7.92 | 73.7 ± 8.07 | 73.9 ± 8.02 |
| Sex: Female, Male(Participants) | Placebo | Apalutamide | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 401 | 806 | 1207 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Apalutamide | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 11 | 16 |
| Not Hispanic or Latino | 338 | 659 | 997 |
| Unknown or Not Reported | 58 | 136 | 194 |
| Race (NIH/OMB)(Participants) | Placebo | Apalutamide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 4 | 4 |
| Asian | 47 | 93 | 140 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 20 | 48 | 68 |
| White | 276 | 524 | 800 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 58 | 136 | 194 |
| Region of Enrollment(Participants) | Placebo | Apalutamide | Total |
|---|---|---|---|
| Australia | 11 | 30 | 41 |
| Austria | 2 | 4 | 6 |
| Belgium | 3 | 4 | 7 |
| Canada | 21 | 61 | 82 |
| Czech Republic | 14 | 20 | 34 |
| Denmark | 7 | 14 | 21 |
| Finland | 5 | 7 | 12 |
| France | 21 | 39 | 60 |
| Germany | 20 | 31 | 51 |
| Hungary | 1 | 4 | 5 |
| Israel | 7 | 7 | 14 |
| Italy | 12 | 24 | 36 |
| Japan | 21 | 34 | 55 |
| Netherlands | 11 | 8 | 19 |
| New Zealand | 2 | 6 | 8 |
| Norway | 3 | 4 | 7 |
| Poland | 6 | 28 | 34 |
| Romania | 5 | 7 | 12 |
| Russia | 11 | 24 | 35 |
| Slovakia | 6 | 11 | 17 |
| South Africa | 17 | 35 | 52 |
| Spain | 36 | 95 | 131 |
| Sweden | 3 | 10 | 13 |
| Taiwan, Province Of China | 5 | 14 | 19 |
| United Kingdom | 38 | 61 | 99 |
| United States | 113 | 224 | 337 |
Showing the first 100 of 379 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2013 to primary completion in May 2017, 43 months.
Results were first posted in Jun 2018, 1 year 1 month after primary completion.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 43 months is above that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apalutamide
Aragon Pharmaceuticals, Inc. →